Fidelity SPDR Advertisement
Home > Boards > US OTC > Delisted > GTC Biotherapeutics (fka GTCB)

Re: Expiration dates of Rituxan patents

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 488
Posts 82,076
Boards Moderated 24
Alias Born 09/05/02
160x600 placeholder
No Iran Nuclear Deal Seen by Monday Deadline
U.S. officials are arguing that preserving improved relations with Tehran is preferable to a breakdown in more than a year of direct negotiations and a potential escalation of tensions in an already-fractious Middle East.
China Mobile's Need for Speed -- Barron's Asia
Intel Projects More Growth in 2015 -- Update
Zoetis Unveils $500 Million Stock Buyback Plan -- Update
Appeals Court Grants TV Programmers Stay in FCC Dispute -- Update
Technip Bids for CGG -- 2nd Update
Wireless Carriers Bid Up US Airwaves To Record
Faith-Based Shareholders Prepare Day of Reckoning for Bank of America
In Social-Media Era, When Is Free Speech Illegal?
Chinese Premier Plays Down Qualcomm's Woes
DewDiligence Member Level  Saturday, 03/15/08 06:12:36 PM
Re: masterlongevity post# 8871
Post # of 19307 
Re: Expiration dates of Rituxan patents

According to DNA itself, the US patents that protect Rituxan are 5,677,180 (“Chimeric antibody with specificity to human B cell surface antigen”) and 5,736,137 (“Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma”).

The ‘180’ patent expires in Oct 2014 and the ‘1378’ patent expires in Apr 2015.

GTC believes that only the ‘180’ patent is relevant to GTC’s CD20 mAb program.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist